Tirzepatide and metformin for PCOS: RCT

A small randomised trial from China reports that adding low-dose tirzepatide to metformin produced roughly six times more weight loss than metformin alone over 16 weeks in overweight women with polycystic ovary syndrome (PCOS)^[1]. The study, published in Diabetes, Obesity & Metabolism on 3 June 2026, is one of the first prospective, randomised trials to test tirzepatide specifically in a PCOS population.

What the trial measured

Sixty overweight or obese Chinese women with PCOS were randomly assigned to one of two arms: metformin 1 000 mg twice daily (MET group), or metformin at the same dose plus tirzepatide 5 mg once weekly (COM group). Treatment lasted 16 weeks. The primary outcomes were changes in body weight, BMI and visceral adipose tissue (VAT)^[1].

At week 16, the combination group lost a mean of 10.4 kg (standard deviation 3.5 kg) compared with 1.7 kg (SD 2.5 kg) in the metformin-only group (p < 0.001). BMI fell by 4.12 points in the combination arm versus 0.68 points in the metformin arm. Visceral fat area, measured by imaging, dropped by 34.1 cm squared versus 4.7 cm squared. All three differences reached statistical significance at the p < 0.001 level^[1].

The visceral fat finding matters because visceral adiposity is thought to drive much of the insulin resistance and chronic low-grade inflammation that worsen PCOS symptoms. Reducing it is a common clinical goal, but metformin alone rarely produces large changes in body composition over four months.

Reproductive outcomes

The combination group also showed a higher rate of menstrual cycle recovery (p = 0.013) and a higher total pregnancy rate (p = 0.014) during the treatment window. The authors attribute these improvements to better insulin sensitivity and lower androgen levels, both of which are key drivers of anovulation in PCOS^[1].

PCOS affects an estimated 8 to 13 percent of women of reproductive age worldwide, and many of those affected are overweight or obese. Weight loss of 5 to 10 percent is already known to restore ovulatory cycles in a proportion of these women, so a therapy that consistently delivers double-digit kilogram losses could have outsized reproductive benefits if the finding holds in larger cohorts.

What this trial does not tell us

The sample was small (60 women), open-label, and drawn from a single Chinese centre. Participants received only the lowest available tirzepatide dose (5 mg weekly), which is the starting dose in the approved Mounjaro label for type 2 diabetes and obesity^[2]. No dose escalation was attempted, so the results do not reflect the higher doses (10 or 15 mg) used in the SURMOUNT weight-management programme.

Follow-up ended at 16 weeks. We do not know whether the weight stayed off, whether menstrual regularity persisted, or how pregnancies progressed after the trial window closed. The open-label design also introduces the possibility of expectation bias, because both patients and investigators knew which treatment each participant was receiving.

The study population was entirely Chinese, which limits how directly the findings translate to other ethnic groups. Metabolic responses to both metformin and incretin therapies can vary across populations, and PCOS itself presents differently depending on genetic background and dietary environment.

Where tirzepatide stands in PCOS research

A May 2026 evidence map in the journal Drugs concluded that tirzepatide still lacked PCOS-specific clinical data and called incretin-based therapies "powerful, but still adjunctive, weight-loss agents" rather than disease-modifying treatments for the syndrome^[3]. The Yang et al. trial partially fills that gap by providing the first randomised human data, but it remains a single, small-sample study.

Preclinical work is also progressing. A 2026 rat-model study found that tirzepatide reduced testosterone, improved follicle development and lowered inflammatory markers in PCOS-induced animals, mirroring the metabolic improvements seen in the Chinese trial^[4]. The rat data adds biological plausibility but, as with all animal work, the doses and metabolic context do not map directly onto human treatment.

What to watch next

Eli Lilly's larger, placebo-controlled PCOS trial (registered on ClinicalTrials.gov) is still recruiting and uses a 72-week treatment window. Results from that study will carry more statistical weight and longer follow-up than the 16-week Chinese data. Until then, this trial is an early signal, not a clinical standard. Anyone considering tirzepatide for PCOS should discuss the evidence with a clinician, because the drug is not yet approved for this indication in any jurisdiction^[2].